Skip to content

Role of Mamejava ghanvati tablet and Trikatu gutika tablet in diabetes mellitus

A comparative study of Mamajjaka ghanvati and Trikatu gutika in the management of Madhumeha(Type-II Diabetes Mellitus)

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2017/02/007971
Enrollment
30
Registered
2017-02-27
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Madhumeha (Type 2 Diabetes mellitus)

Interventions

Intervention1: GROUP A Mamajjaka ghanvati : 4 tablets thrice a day with luke warm water for 8 weeks Control Intervention1: Group B Trikatu gutika: 4 tablets thrice a day with luke warm water for 8

Sponsors

Govt Akhandanand Ayurved College Ahmedabad
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1 Patients with signs and symptoms of Madhumeha as per Ayurveda texts and Diabetes mellitus (type 2) according to modern medicine. 2 Uncontrolled D.M. type 2 even after taking modern anti-diabetic drugs will be treated and their anti-diabetic drug will be continued with thesis drugs 3 Newly detected D.M. type 2 patients and those who have not yet started anti-diabetic drugs 4 Patients fulfilling the standard diagnostic criteria of W.H.O Patients having Fasting blood sugar level 126 mg/dl & Post prandial blood sugar level 200 mg/dl will be taken for study

Exclusion criteria

Exclusion criteria: 1 Age of patient below 20 years and above 60 years 2 Patients of Insulin dependent diabetes mellitus 3 Type 2 diabetes mellitus patients taking insulin 4 Patients having controlled blood sugar levels 5 FBS more than 300 and PPBS more than 350 mg/dl 6 Patients having D.M. with any systemic diseases and complication 7 Patient with Gestational-Diabetes Diabetic Nephropathy retinopathy and neuropathy Carcinoma cardiovascular diseases etc Complicated cases will not be taken for study

Design outcomes

Primary

MeasureTime frame
The results will be assessed on the basis of difference in the score of signs and symptoms OF Madhumeha and improvement in FBS & PPBS before and after treatmentTimepoint: 8 Weeks

Secondary

MeasureTime frame
NILTimepoint: NIL

Countries

India

Contacts

Public ContactDilipkumar Raghavbhai Kataria

IPGT AND RA Jamnagar

patanjaliayucare@yahoo.com09426336822

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026